Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Stock Information
02186.HK
Volume:52,577,507
1.45
-0.1  (-6.17%)
Announcement & Circular
11-17
2026
VOLUNTARY ANNOUNCEMENT APPROVAL OBTAINED FOR THE GROUP'S INNOVATIVE DRUG LY03021 FOR CLINICAL TRIALS IN THE U.S.
11-15
2026
VOLUNTARY ANNOUNCEMENT RENEWED INCLUSION OF THE GROUP'S INNOVATIVE ANTIDEPRESSANT RUOXINLIN IN CHINA'S 2026 NATIONAL REIMBURSEMENT DRUG LIST
11-05
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
10-07
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
09-29
2026
Interim Report 2026
09-04
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2026
08-30
2026
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026
08-20
2026
VOLUNTARY ANNOUNCEMENT MRNA VACCINE LY01620 FOR THE TREATMENT OF CERVICAL PRECANCEROUS LESIONS AND HPV-RELATED TUMORS TO ENTER INTO PHASE II CLINICAL TRIAL IN CHINA
08-17
2026
NOTICE OF BOARD MEETING
08-06
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2026
1
2
3
4
5